A Phase 2 interventional study of Gemcitabine and cisplatin in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 2 sites in 2 countries. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-11-11.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.
Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 43rd largest by enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2002, is one of 65 in phase 2, and was the 22nd registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Margaret Gatti-Mays · Sites in United States
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 73 · Phase 3 19
First in 1997; this study’s year is marked. 9 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is close to the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 90 interventional studies. Of the 78 that completed or were terminated, 34 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 58th largest by enrollment of the 80 interventional ones that give a count, is one of 5 that started in 2002, is one of 41 in phase 2, and was the 11th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
1 of the studies testing gemcitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06026657Margaret Gatti-MaysGemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies testing gemcitabine in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the objective tumor response of the first-line therapy combination of gemcitabine and cisplatin in patients with metastatic breast cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Gemcitabine · Drug: cisplatin
Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
Objective Tumor Response
Best response recorded from the start of treatment until disease progression/recurrence using World Health Organization (WHO) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
Time frame: baseline to measured progressive disease (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration. Data collected every 4 months.)
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
Time frame: first documented complete or partial response to measured progressive disease (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)
Time to Progressive Disease
Defined as the time from study enrollment to the first date of disease progression.
Time frame: first active treatment dose to measured progressive disease (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)
Time to Treatment Failure
Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment.
Time frame: first active treatment dose to last contact for patients, death as a result of any cause, or early discontinuation of treatment (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)
Survival Time
Overall survival is the duration from enrollment to death due to any cause.
Time frame: first active treatment dose to date of death due to any cause (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)
Number of Participants With Maximum Common Toxicity Criteria-National Cancer Institute Toxicity (CTC-NCI) of Gemcitabine-Cisplatin Combination
The CTC provides descriptive terminology for adverse event reporting. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death).
Time frame: Baseline up to 30 days after last dose of study drug (eight 21-day cycles of therapy)
Number of Participants With Hematology Maximum Common Toxicity Criteria - National Cancer Institute Grades
Maximum CTC-NCI toxicity grade for hematology. Grades range from 0 (none) to 5 (death).
Time frame: Baseline up to 30 days after last dose of study drug (eight 21-day cycles of therapy)
Number of Deaths
Time frame: Baseline through follow-up (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)
Number of Participants With Adverse Events Leading to Discontinuation
Time frame: Baseline through eight 21-day cycles
| Milestone | Gemcitabine + Cisplatin |
|---|---|
| Started | 70 |
| Treated | 67 |
| Completed | 30 |
| Not completed | 40 |
| Withdrew: Adverse event | 2 |
| Withdrew: Disease progression or relapse | 24 |
| Withdrew: Death | 2 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Physician decision | 2 |
| Withdrew: Withdrawal by subject | 7 |
Best response recorded from the start of treatment until disease progression/recurrence using World Health Organization (WHO) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
| participants | Gemcitabine + Cisplatin |
|---|---|
| Complete Response | 7 |
| Partial Response | 19 |
| Stable Disease | 19 |
| Progressive Disease | 5 |
| Not Assessable | 4 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
| weeks | Gemcitabine + Cisplatin |
|---|---|
| Duration of Response | 32.7 (26.9 to 48.6) |
Defined as the time from study enrollment to the first date of disease progression.
| weeks | Gemcitabine + Cisplatin |
|---|---|
| Time to Progressive Disease | 33.9 (23.9 to 48.0) |
Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment.
| weeks | Gemcitabine + Cisplatin |
|---|---|
| Time to Treatment Failure | 26.2 (19.6 to 34.9) |
Overall survival is the duration from enrollment to death due to any cause.
| weeks | Gemcitabine + Cisplatin |
|---|---|
| Survival Time | 84.0 (58.6 to 119.3) |
The CTC provides descriptive terminology for adverse event reporting. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death).
| participants | Gemcitabine + Cisplatin |
|---|---|
| Allergic reaction/hypersensivity - Grade 1 | 1 |
| Allergic reaction/hypersensivity - Grade 2 | 1 |
| Allergic reaction/hypersensivity - Grade 3 | 0 |
| Allergic reaction/hypersensivity - Grade 4 | 0 |
| Allergic rhinitis - Grade 1 | 1 |
| Allergic rhinitis - Grade 2 | 0 |
| Allergic rhinitis - Grade 3 | 0 |
| Allergic rhinitis - Grade 4 | 0 |
| Other auditory/hearing - Grade 1 | 0 |
| Other auditory/hearing - Grade 2 | 0 |
| Other auditory/hearing - Grade 3 | 1 |
| Other auditory/hearing - Grade 4 | 0 |
| Blood/Bone marrow - other - Grade 1 | 0 |
| Blood/Bone marrow - other - Grade 2 | 0 |
| Blood/Bone marrow - other - Grade 3 | 0 |
| Blood/Bone marrow - other - Grade 4 | 1 |
| Cardiac- ischemia/infarction - Grade 1 | 0 |
| Cardiac- ischemia/infarction - Grade 2 | 0 |
| Cardiac- ischemia/infarction - Grade 3 | 1 |
| Cardiac- ischemia/infarction - Grade 4 | 0 |
| Hypertension - Grade 1 | 0 |
| Hypertension - Grade 2 | 1 |
| Hypertension - Grade 3 | 0 |
| Hypertension - Grade 4 | 0 |
| Hypotension - Grade 1 | 0 |
| Hypotension - Grade 2 | 0 |
| Hypotension - Grade 3 | 0 |
| Hypotension - Grade 4 | 1 |
| Fatigue - Grade 1 | 6 |
| Fatigue - Grade 2 | 1 |
| Fatigue - Grade 3 | 0 |
| Fatigue - Grade 4 | 0 |
| Fever - Grade 1 | 0 |
| Fever - Grade 2 | 1 |
| Fever - Grade 3 | 0 |
| Fever - Grade 4 | 0 |
| Rigors, chills - Grade 1 | 1 |
| Rigors, chills - Grade 2 | 0 |
| Rigors, chills - Grade 3 | 0 |
| Rigors, chills - Grade 4 | 0 |
| Weight loss - Grade 1 | 1 |
| Weight loss - Grade 2 | 1 |
| Weight loss - Grade 3 | 0 |
| Weight loss - Grade 4 | 0 |
| Alopecia - Grade 1 | 1 |
| Alopecia - Grade 2 | 3 |
| Alopecia - Grade 3 | 0 |
| Alopecia - Grade 4 | 0 |
| Rash/desquamation - Grade 1 | 0 |
| Rash/desquamation - Grade 2 | 0 |
| Rash/desquamation - Grade 3 | 1 |
| Rash/desquamation - Grade 4 | 0 |
| Anorexia - Grade 1 | 4 |
| Anorexia - Grade 2 | 0 |
| Anorexia - Grade 3 | 0 |
| Anorexia - Grade 4 | 0 |
| Constipation - Grade 1 | 1 |
| Constipation - Grade 2 | 0 |
| Constipation - Grade 3 | 0 |
| Constipation - Grade 4 | 0 |
| Mucositis due to radiation - Grade 1 | 2 |
| Mucositis due to radiation - Grade 2 | 0 |
| Mucositis due to radiation - Grade 3 | 0 |
| Mucositis due to radiation - Grade 4 | 0 |
| Nausea - Grade 1 | 10 |
| Nausea - Grade 2 | 8 |
| Nausea - Grade 3 | 2 |
| Nausea - Grade 4 | 0 |
| Vomiting - Grade 1 | 4 |
| Vomiting - Grade 2 | 7 |
| Vomiting - Grade 3 | 1 |
| Vomiting - Grade 4 | 0 |
| SGPT (ALT) - Grade 1 | 0 |
| SGPT (ALT) - Grade 2 | 1 |
| SGPT (ALT) - Grade 3 | 0 |
| SGPT (ALT) - Grade 4 | 0 |
| Infection without neutropenia - Grade 1 | 1 |
| Infection without neutropenia - Grade 2 | 0 |
| Infection without neutropenia - Grade 3 | 0 |
| Infection without neutropenia - Grade 4 | 0 |
| Insomnia - Grade 1 | 0 |
| Insomnia - Grade 2 | 0 |
| Insomnia - Grade 3 | 1 |
| Insomnia - Grade 4 | 0 |
| Abdominal pain or cramping - Grade 1 | 1 |
| Abdominal pain or cramping - Grade 2 | 1 |
| Abdominal pain or cramping - Grade 3 | 0 |
| Abdominal pain or cramping - Grade 4 | 0 |
| Headache - Grade 1 | 0 |
| Headache - Grade 2 | 0 |
| Headache - Grade 3 | 1 |
| Headache - Grade 4 | 0 |
| Pain - Other - Grade 1 | 0 |
| Pain - Other - Grade 2 | 0 |
| Pain - Other - Grade 3 | 1 |
| Pain - Other - Grade 4 | 0 |
| Renal/Genitourinary - Other - Grade 1 | 1 |
| Renal/Genitourinary - Other - Grade 2 | 0 |
| Renal/Genitourinary - Other - Grade 3 | 1 |
| Renal/Genitourinary - Other - Grade 4 | 0 |
Maximum CTC-NCI toxicity grade for hematology. Grades range from 0 (none) to 5 (death).
| participants | Gemcitabine + Cisplatin |
|---|---|
| Hemoglobin (g/L) - Grade 1 | 35 |
| Hemoglobin (g/L) - Grade 2 | 20 |
| Hemoglobin (g/L) - Grade 3 | 5 |
| Hemoglobin (g/L) - Grade 4 | 1 |
| Neutrophils (x10E9/L) - Grade 1 | 6 |
| Neutrophils (x10E9/L) - Grade 2 | 25 |
| Neutrophils (x10E9/L) - Grade 3 | 13 |
| Neutrophils (x10E9/L) - Grade 4 | 10 |
| Platelets (x10E9/L) - Grade 1 | 43 |
| Platelets (x10E9/L) - Grade 2 | 2 |
| Platelets (x10E9/L) - Grade 3 | 1 |
| Platelets (x10E9/L) - Grade 4 | 0 |
| White Blood Cells (x10E9/L) - Grade 1 | 16 |
| White Blood Cells (x10E9/L) - Grade 2 | 27 |
| White Blood Cells (x10E9/L) - Grade 3 | 18 |
| White Blood Cells (x10E9/L) - Grade 4 | 3 |
| participants | Gemcitabine + Cisplatin |
|---|---|
| Disease Progression | 35 |
| Ventricular Fibrillation | 1 |
| Circulatory Arrest | 1 |
| participants | Gemcitabine + Cisplatin |
|---|---|
| Patients with >=1 AE leading to discontinuation | 2 |
| Pneumonia | 1 |
| Toxic skin eruption | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine + Cisplatin | — | — | — |
| Event | Gemcitabine + Cisplatin |
|---|---|
| Atrial fibrillationCardiac disorders | 1/67 |
| Ventricular fibrillationCardiac disorders | 1/67 |
| Gastrointestinal perforationGastrointestinal disorders | 1/67 |
| PeriproctitisGastrointestinal disorders | 1/67 |
| General physical health deteriorationGeneral disorders | 1/67 |
| Escherichia sepsisInfections and infestations | 1/67 |
| PneumoniaInfections and infestations | 1/67 |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/67 |
| Renal failure acuteRenal and urinary disorders | 1/67 |
| PleurisyRespiratory, thoracic and mediastinal disorders | 1/67 |
| Event | Gemcitabine + Cisplatin |
|---|---|
| NauseaGastrointestinal disorders | 23/67 |
| NeutropeniaBlood and lymphatic system disorders | 16/67 |
| AstheniaGeneral disorders | 14/67 |
| VomitingGastrointestinal disorders | 12/67 |
| HyperkalaemiaMetabolism and nutrition disorders | 9/67 |
| Weight decreasedInvestigations | 7/67 |
| HypocalcaemiaMetabolism and nutrition disorders | 6/67 |
| HypercalcaemiaMetabolism and nutrition disorders | 5/67 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/67 |
| AlopeciaSkin and subcutaneous tissue disorders | 4/67 |
| Age Continuous(years) | Gemcitabine + Cisplatin |
|---|---|
| Mean | 50.5 ± 9.7 |
| Sex: Female, Male(Participants) | Gemcitabine + Cisplatin |
|---|---|
| Female | 70 |
| Male | 0 |
| Region of Enrollment(participants) | Gemcitabine + Cisplatin |
|---|---|
| Russian Federation | 63 |
| Germany | 7 |
| Menopausal Status(participants) | Gemcitabine + Cisplatin |
|---|---|
| Pre-menopausal | 16 |
| Post-menopausal | 54 |
| Pathological Diagnosis(participants) | Gemcitabine + Cisplatin |
|---|---|
| Ductal breast carcinoma | 44 |
| Ductal and lobular breast carcinoma | 2 |
| Lobular breast carcinoma | 5 |
| Mucinous breast carcinoma | 1 |
| Adenocystic breast carcinoma | 10 |
| Papillary carcinoma | 1 |
| Unknown | 7 |
| Stage of Disease at Entry to the Study(participants) | Gemcitabine + Cisplatin |
|---|---|
| Stage IIIb | 1 |
| Stage IV | 69 |
| Stage of Disease at Time of Diagnosis(participants) | Gemcitabine + Cisplatin |
|---|---|
| Stage I | 3 |
| Stage IIa | 13 |
| Stage IIb | 22 |
| Stage IIIa | 12 |
| Stage IIIb | 15 |
| Stage IV | 5 |
| Time from Initial Diagnosis to Study Entry(month) | Gemcitabine + Cisplatin |
|---|---|
| Mean | 37.6 ± 39.7 |
The record gives a start of Oct 2002 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Cisplatin